Chordia Looks To Forge Own Path In Oncology
Japan Venture Progresses Ex-Takeda Assets
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
